The Science Journal of the Lander
College of Arts and Sciences
Volume 9
Number 2 Spring 2016
1-1-2016

Oocyte Cryopreservation
Esther Gellis
Touro College

Follow this and additional works at: https://touroscholar.touro.edu/sjlcas
Part of the Obstetrics and Gynecology Commons

Recommended Citation
Gellis, E. (2016). Oocyte Cryopreservation. The Science Journal of the Lander College of Arts and
Sciences, 9(2). Retrieved from https://touroscholar.touro.edu/sjlcas/vol9/iss2/7

This Article is brought to you for free and open access by the Lander College of Arts and Sciences at Touro Scholar.
It has been accepted for inclusion in The Science Journal of the Lander College of Arts and Sciences by an
authorized editor of Touro Scholar. For more information, please contact touro.scholar@touro.edu.

-

Oocyte Cryopreservation
Esther Gellis

Esther Gellis is graduating in January 2017 with a BS in Biology.

Abstract
Anti-mitotic therapies are a form of therapy used to treat cancer patients. The use of these treatments on females
can result in fertility complications. Therefore, prior to treatment, women must seek ways to preserve their ability to
conceive children after receiving treatment. This study analyzes the outcomes of oocyte cryopreservation and its many
variables. Three important variables that can affect the outcome of oocyte cryopreservation are age, cryopreservation
method and cryoprotectants. Evidence indicates that human oocyte cryopreservation can enable a woman to preserve
her ability to give birth to a healthy child, following anti-mitotic therapies. Hundreds of babies have been born as a result
of oocyte cryopreservation. Oocyte cryopreservation can even enable a woman with ovarian cancer to have a healthy
offspring, post treatment.
Introduction
Early detection of cancer along with modern medicine has led
to a rise in the survival rates of young cancer patients. This
results in many cancer survivors who are capable of childbearing. However, since chemotherapy and radiation given during
the cancer curing process can result in various fertility issues,
patients must find a method to preserve their ability to give
birth to children.
One method of preservation is oocyte cryopreservation.
Human oocyte cryopreservation is a procedure in which a
woman’s oocytes are extracted, frozen and then stored. When
the woman desires to become pregnant the eggs are thawed,
fertilized and transferred in to the uterus.
This type of preservation is preferred by many for various reasons. Many single cancer patients prefer freezing unfertilized
eggs, as opposed to fertilized ones, as they don’t need any male
donors at the time. Another reason women may want to freeze
eggs is due to the fact that oocyte quality and quantity diminishes with age. This can cause a lack of healthy eggs to allow for
pregnancy. Considering this, many women may prefer to freeze
their healthy young and vital oocytes, which are more likely to
produce pregnancies.
Furthermore, people may consider oocyte cryopreservation
due to ethical, legal and religious hindrances that prevent them
from doing embryo cryopreservation. Couples may not want to
cryopreserve embryos as the embryos may have to be disposed
if the cancer patient dies. (Noyes, et. al. 2010)
The goal of this study is to determine if oocyte cryopreservation is a means that enables women to have healthy offspring,
post anti-mitotic therapy.

Methods
Pub med.gov, google scholar and Touro databases such as,
EBSCO host, were used to research relevant studies and reviews for the background, process and results of oocyte cryopreservation. The review paper’s references were used to find
additional original papers that were relevant to the question
proposed above. Key words such as oocyte cryopreservation,

oocyte cryopreservation in cancer patients, slow freezing and
vitrification were used in order to find articles.

Discussion
Various studies were done on oocyte cryopreservation. In one
experiment, twenty-two cancer patients, between ages 21 and
38, underwent cycles of oocyte cryopreservation. After drug
stimulation, oocytes were harvested from sixteen of the twenty-two infertile women, subsequently fertilized and implanted in
them. The other six infertile patients received donor eggs. Only
mature oocytes were preserved. The eggs were preserved by
two methods, slow cooling method and vitrification. A total of
295/355 oocytes were recovered with a 92% survival rate.
At the time of publication of the study, fourteen of the patients
had become pregnant, one had miscarried, and three pregnancies were still ongoing. A total of thirteen babies were born to
the other expectant ten patients. Eleven of these babies were
completely healthy, however a set of twins were born prematurely due to premature dilatation of an incompetent cervix.
These twins suffered some complications of prematurity, but
upon reaching two years of age, the twins were thriving within
the average norms. Besides for two cases of gestational diabetes, no other complications were reported (Grifo, Noyes, 2010).
Gestational diabetes is common in women during pregnancy.
According to the CDC, the ratio of women with gestational
diabetes ranges between one in every twenty to one in every
fifty of expectant women.
Additionally, Dr. Nicole Noyas and other researchers pooled
together data to see how many oocyte cryopreservation’s resulted in normal babies. Any incomplete data was left out. A
total of six hundred and nine births were reported between
the years 1986-2008. All the babies born were a result of oocyte cryopreservation. However, the oocytes in those six hundred and nine births were preserved using different methods
of cryopreservation. Three hundred and eight went through
the process of slow freezing, two hundred eighty nine were
preserved using vitrification and twelve had a combination of
slow freezing and vitrification. A total of eight anomalies were
reported. There were also three hundred twenty seven cryopreserved oocyte births published, totaling nine hundred thirty
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six births. Out of the nine hundred thirty six babies, twelve babies were born with birth defects. Overall the anomaly rate is
1.3%. According to the CDC, three percent of babies are born
with major structural or genetic defects.The twelve defects and
the total incidents statistically occurring in natural conception
babies compared to oocyte cryopreservation babies are listed
in table 1. (Noyes, et. al. 2009)

Table1
Birth Anomaly

Approximate
incidence in
natural conception births

Incidence in total
of 936 oocyte
cryopreservation
births (n)

All

One in 33

Skin hemangioma

One in 50–225

1

Cardiac defects

One in 125

3

Neural tube defects

One in 385

0

Cleft lip and palate

One in 710

1

Clubfoot

One in 735

3

Arnold-Chiari syndrome

One in 1200

1

Choanal atresia

One in 7000

1

Biliary atresia

One in 10,000–
15,000

1

Rubinstein-Taybi
syndrome

One in
100,000–
125,000

1

12 (one in 78)

Birth anomalies in natural conception versus oocyte cryopreservation,
listed most common to most rare.
Adapted from N. Noyes, E. Porcu & A. Borini, 2009

From the table one can assess that there were no neural tube
defects and that the defect of skin hemangioma is the same
range as babies born from natural conception. Additionally, cleft
lip and palate as well as cardiac defects occurred less in the
babies born as a result of oocyte cryopreservation.
Researchers have tried to improve the process of oocyte
cryopreservation. One issue that arose from freezing the eggs
was that extensive intracellular ice formed during freezing.
Extensive intracellular ice can cause cellular disruption in the
oocyte during the oocyte cryopreservation process. This can
possibly be improved by using cryoprotectants such as, propanediol and sucrose to increase the extent of the dehydration
process. The aim of the study done by researchers in Infertility
and IVF Center of Buda was to introduce their preliminary clinical results with oocyte cryopreservation.They used slow cooling as the procedure to freeze the eggs. They specifically used
propanediol (1.5M) and sucrose (0.3 M) as the cryoprotectants.
After incubating the oocytes for 4-6 hours, the oocytes were
thawed, fertilized and embryos were transferred into twenty-nine patients. Out of one hundred ten cryopreserved eggs,
eighty-four survived. This is a 76% survival rate, which is high
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but not optimal. From fifty-two embryo transfers, seven resulted in clinical pregnancies, which is 7.3% implantation rate per
egg thawed. Chorion biopsies that were performed indicated
that there were no chromosomal abnormalities. Out of the
seven pregnancies, five of them resulted in four singletons and
one set of twins. One was still ongoing at the time of the study
and the seventh spontaneously aborted in the tenth week. No
abnormalities were indicated in the study. Additionally, there
was only a small difference in the pregnancy rate, 33% versus
24%, between those pregnancies that resulted from frozen oocytes and those that resulted from fresh oocytes. As indicated
from published literature at that time of the research, fifteen to
thirty oocytes were needed in order to achieve one pregnancy.
Previously, one hundred to one hundred fifty were needed to
achieve one pregnancy. (Konc, et. al. 2008) The results show
that oocyte cryopreservation is improving over time.
Vitrification is also known as ultra-rapid cooling. In recent years,
vitrification has proven the superior method. Compared to
slow freezing, vitrification results in higher oocyte survival and
fertilization. (Cil, et. al. 2013) In a study done to compare the
outcome of the two methods, the survival, fertilization, pregnancy and implantation rates were 57.9% versus 78.9%, 64.6%
versus 72.8%, 7.6% versus 18.2% and 4.3% versus 9.3% correspondingly.The rates were higher in all steps for the vitrification
method. (Fadini, et al., 2009)
The duration of cryostorage doesn’t undesirably affect the
thawing of frozen oocytes. A study was done to see if there is
any influence on the outcome of thawing cryopreserved oocytes. There were three groups in the experiment. Group A’s
eggs were cryostored for one to three months, group B’s eggs
were cryostored for four to six months and group C’s were
cryostored for seven to forty eight months. Group C was further divided into three subgroups. Group C1, was cryostored
for seven to nine months, group C2 was cryostored for ten
to twelve months and group C3 was cryostored for a total of
thirteen to forty eight months. The researchers found no significant difference, from groups A, B and C, in the main outcome
measurements, which were oocyte survival after thawing, fertilization, implantation, embryo development and quality and birth.
Oocytes can be cryopreserved for numerous years without
having an effect on the oocytes quality and performance after
thawing. (Parmegiani, et. al. 2009)
One factor that may affect the outcome of oocyte cryopreservation is the age.The value of freezing an older woman’s oocytes
is controversial. (Zhang, et. al. 2015) The rate of implantation of
the fertilized egg that resulted from the slow freezing and vitrification methods declines with age. A study was done to collect
data on the probability of live birth as of function of age. The
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researchers found that live births occur from the slow freezing method until age forty-two, and until age forty-four from
the vitrification method. They limited their results to the age
range of twenty five to forty two years old, as there were only
few cycles that were above or below the twenty-five through
forty-two year old range. This study’s data was on patients that
were infertile. The study was not specifically performed on post
cancer patients. (Cil, et. al. 2013)
Furthermore, a study was implemented in order to report the
oocyte cryopreservation experience in women aged forty and
older. One hundred fifty eight women, aged forty to forty-nine,
underwent minimal ovarian stimulation to retrieve their eggs. A
total of five hundred thirty two eggs were retrieved and frozen.
Four of the women did not have any oocytes retrieved. A total
of four hundred eighty five embryos were formed. Out of the
four hundred eighty five embryos, only fifty-seven were relatively
healthy. Six clinical pregnancies were achieved. Only three resulted
in live births. There was a 5.3 % live birth rate per embryo transfer. The other three pregnancies were spontaneously aborted. As
per the data, a woman aged forty and older can give birth to a
baby after undergoing the process of freezing her eggs. However,
there is a low chance that it will indeed happen, as there is a 5.3%
chance that the woman will give birth. (Zhang, et. al. 2015)
A woman who has ovarian cancer may risk surgical menopause.
Oocyte cryopreservation can be an option for woman facing
ovarian cancer. It could also help patients that need to have a
one or both ovaries removed. A twenty six year old woman
with borderline ovarian tumors had her oocytes cryopreserved
after a right adnexectomy. Seven mature eggs were retrieved
and frozen. Thirty-nine months later, the woman underwent
a left ovariectomy. Three embryos were transferred into the
woman’s uterus. Endometrial growth was achieved with the
help of hormonal replacement treatment.The woman gave birth
to healthy twin babies. (Porcu, et al., 2008)
Oocyte cryopreservation can help women have healthy babies
even when they don’t have their own healthy eggs. Remaining
eggs from oocyte cryopreservation cycles can be saved and
donated to another couple that are experiencing fertility complications. A study was done in which twenty-eight infertile
women froze their oocytes. Twelve of the twenty-eight women
had their frozen oocytes thawed.Three of the women used their
own eggs in IVF treatment and the other twelve donated their
eggs to other women. Premature ovarian failure, physiological
menopause, abnormal karyotype and poor ovarian reserve are
the reasons that the twelve women needed to receive oocytes
from other women. Seven women became pregnant. Six of the
seven used donated oocytes. A total of 6 healthy babies were
born including a set of twins. The other 2 pregnancies were

aborted due to a blighted ovum. (Li, et al., 2005)
Oocyte cryopreservation may not be for everyone. Women
with cancers that need to be treated immediately after diagnosis, may not be a candidate for oocyte cryopreservation. This is
because oocyte cryopreservation requires ovarian stimulation
and retrieval. This can take an average of twelve days. (Noyes,
et al., 2011) Additionally, some women that have breast cancer
might run into issues with preserving their eggs. This is because
estrogen levels rise during ovarian stimulation. High levels of
estrogen might not be safe for women with breast cancer.
(Rodriguez-Wallberg, Oktay, 2010)
Furthermore, some women may not want to undergo oocyte
cryopreservation as it can cause a woman to have a risk having of intra-abdominal bleeding and ovarian hyper stimulation
syndrome. However, there is a very low percentage rate of this
risk. (Noyes, et al., 2011) Additionally, women with cancers may
not be able to cryopreserve their eggs due to economic issues.
It is a very expensive procedure. According to NYU Langone
Medical Center’s website, oocyte cryopreservation can cost
about $16,000- $20,000. This includes initial office consultation, egg cryopreservation cycle, prerequisite blood testing and
screening medication. As of 2010, cancer patients are generally
not offered insurance coverage for oocyte cryopreservation.
(Noyes, et al., 2011) Consequently, cryopreservation may not
be an option for people that are struggling financially.

Conclusion
Oocyte cryopreservation is a viable method that enables
women post mitotic therapies to have healthy offspring. As per
the research discussed above, many women were able to have
a healthy baby because they froze their oocytes. Even when
abnormalities were reported, they were basically within normal range. Oocyte cryopreservation has even enabled a woman
with borderline ovarian cancer to have a healthy offspring.
Even though the value of freezing an older woman’s oocytes is
controversial and the rate of implantation of the fertilized egg
declines with age, data has shown that oocyte cryopreservation
can enable older women to have healthy babies.
There are different variables that may increase the outcome of
oocyte cryopreservation. The vitrification method has shown
to be the efficient and more reliable method. Cryoprotectants
such as, propanediol and sucrose can increase the extent of
the dehydration process and thereby prevent the oocytes from
disrupting. Furthermore, the duration of cryostorage doesn’t
undesirably affect the outcome of oocyte cryopreservation.
Oocyte cryopreservation may not be for everyone due to economic reasons and timing of the anti-mitotic therapies. However,
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it is a means that enable women to have healthy children even
after their oocyte quality and quantity diminish as result of the
cancer treatment.
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